{"title":"Basic science: (May 2009)","authors":"R. Sutherland","doi":"10.1017/S1470903109990253","DOIUrl":"https://doi.org/10.1017/S1470903109990253","url":null,"abstract":"1. Adamovic T, Roshani L, Chen L, Schaffer BS, Helou K, Levan G, Olsson B, Shull JD. Nonrandom pattern of chromosome aberrations in 17 b-estradiol-induced rat mammary tumors: indications of distinct pathways for tumor development. Genes Chromosomes Cancer 2007; 46: 459–469. 2. Adams BD, Furneaux H, White BA. The microribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-a (ERa) and represses ERa messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007; 21: 1132–1147. 3. Aupperlee MD, Haslam SZ. Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology 2007; 148: 2290–2300. 4. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 2007; 120: 2202–2207. 5. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, AlKuraya K, Janicke F, Sauter G, Simon R. Estrogen receptor a (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007; 39: 655–660. 6. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870–874. 7. Kim H, Chen JJ, Yu XH. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007; 316: 1202–1205. 8. Li W, Xiao C, Vonderhaar BK, Deng CX. A role of estrogen/ERa signaling in BRCA1-associated tissue-specific tumor formation. Oncogene 2007 May 14; [Epub ahead of print], doi:10.1038/sj.onc.1210527. 9. Liu BL, Ordonez-Ercan D, Fan ZY, Edgerton SM, Yang XH, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007; 120: 1874–1882. 10. Maiello MR, D’Alessio A, De Luca A, Carotenuto A, Rachiglio AM, Napolitano M, Cito L, Guzzo A, Normanno N. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat 2007; 102: 275–282. 11. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. ERa-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 2007 May 7; [Epub ahead of print], doi:10.1038/sj.onc.1210468. 12. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 2007; 120: 1883–1890. 13. Paterson AL, Pole JCM, Blood KA, Garcia MJ, Cooke SL, Teschendo","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"1 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2009-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56922283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Basic science: (February 2009)","authors":"R. Sutherland","doi":"10.1017/S147090310999023X","DOIUrl":"https://doi.org/10.1017/S147090310999023X","url":null,"abstract":"1. Ang EZF, Nguyen HT, Sim HL, Putti TC, Lim LHK. Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells. Mol Cancer Res 2009; 7: 266–274. 2. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009; 15: 778–787. 3. Brerner TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP. Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients. Int J Cancer 2009; 124: 896–904. 4. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360: 573–587. 5. Connors SK, Balusu R, Kundu CN, Jaiswal AS, Gairola CG, Narayan S. C/EBP b-mediated transcriptional regulation of bcl-xl gene expression in human breast epithelial cells in response to cigarette smoke condensate. Oncogene 2009; 28: 921–932. 6. de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009; 101: 205–209. 7. Ford CE, Ekstroem EJ, Andersson T. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci U S A 2009; 106: 3919–3924. 8. Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banha AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FOXP3(1) regulatory t cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009; 15: 1046–1051. 9. Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen SL, Chang DK, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 2009; 15: 1317–1325. 10. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009; 28: 843–853. 11. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, Hayran M, Shapiro CL. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2 g expression levels correlate with basal phenotype in breast cancer. Cancer 2009; 115: 899–908. 12. Holm C, Kok M, Michalides R, Fles R, Koornstra RHT, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O, Landberg G, Linn SC. Phosphorylation of the oestrogen receptor a at serine 305 and prediction of tamoxifen resistance in breast cancer. J Path 2009; 217: 372–379. 13. Hong ","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S147090310999023X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56922117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Basic science: (March 2009)","authors":"R. Sutherland","doi":"10.1017/S1470903109990216","DOIUrl":"https://doi.org/10.1017/S1470903109990216","url":null,"abstract":"1. Aaltonen K, Amini RM, Heikkila P, Aittomaki K, Tamminen A, Nevanlinna H, Blomqvist C. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer 2009; 100: 1055–1060. 2. Al-Bazz YO, Underwood JCE, Brown BL, Dobson PRM. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer 2009; 45: 694–704. 3. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of toll-like receptor 9. Clin Cancer Res 2009; 15: 1575–1584. 4. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, Chaffanet M, Maraninchi D, Viens P, Birnbaum D. How different are luminal A and basal breast cancers? Int J Cancer 2009; 124: 1338–1348. 5. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, Lazarus P. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009; 69: 1892–1900. 6. Chisarnore MJ, Wilkinson HA, Flores O, Chen JD. Estrogen-related receptor-a antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts. Mol Cancer Ther 2009; 8: 672–681. 7. Creighton CJ, Osborne CK, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009; 114: 287–299. 8. Eubank TD, Roberts RD, Khan M, Curry JM, Nuovo GJ, Kuppusamyl P, Marsh CB. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res 2009; 69: 2133–2140. 9. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ, Dunn SE. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009; 28: 1421–1431. 10. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114: 263–275. 11. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Coquard IR, Puisieux A, Caux C, Blay JY, Menetrier-Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer ","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56922045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Basic science: (April 2009)","authors":"R. Sutherland","doi":"10.1017/S1470903109990228","DOIUrl":"https://doi.org/10.1017/S1470903109990228","url":null,"abstract":"1. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009; 69: 3589–3596. 2. Andre F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 2009; 10: 381–390. 3. Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y, Inoue S. Association of estrogen receptor a and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 2009; 69: 2935–2940. 4. Barclay JL, Anderson ST, Waters MJ, Curlewis JD. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer 2009; 124: 1756–1766. 5. Cardamone MD, Bardella C, Gutierrez A, Croce LD, Rosenfeld MG, Di Renzo MF, De Bortoli M. ERa as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A 2009; 106: 7420–7425. 6. Cheng CJ, Lin YC, Tsai MT, Chen CS, Hsieh MC, Chen CL, Yang RB. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res 2009; 69: 3634–3641. 7. De Amicis F, Zupo S, Panno ML, Malivindi R, Giordano F, Barone I, Mauro L, Fuqua SAW, Ando S. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor a gene promoter. Mol Endocrinol 2009; 23: 454–465. 8. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 2009; 69: 2817–2825. 9. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009; 15: 2472–2478. 10. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bundgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RKR, Ma Y, Kruger S, Bruch HP, Auer G, Guo NL, Ried T. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 2009; 124: 1552–1564. 11. Kataoka M, Antoniou A, Warren R, Leyland J, Brown J, Audley T, Easton D. Genetic models for the familial aggregation of mammographic breast density. Cancer Epidemiol Biomarkers Prev 2009; 18: 1277–1284. 12. Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A, Sebti SM. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27(Kip1) phosphorylation on Thr187 and accumulates p27(Kip1) in the nucleus: implications for breast cancer therapy. Mol Cell Biol 2009; 29: 2254–2263. 13. Kwek SS, Ro","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990228","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56922103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Breast cancer and pregnancy: diagnosis and treatment options","authors":"E. A. Velde, G. Sonke, E. Rutgers","doi":"10.1017/S1470903109990198","DOIUrl":"https://doi.org/10.1017/S1470903109990198","url":null,"abstract":"A 36-year-old woman had noticed a lump in her right breast, just after she had discovered she had been pregnant for about 6 weeks. At referral to our clinic, on physical examination a palpable mass was found in the upper quadrant of her right breast, sized 2 cm in diameter. Diagnostic mammography and ultrasound were performed elsewhere and showed an uncertain density on mammography and an uncertain hypoechoic structure on ultrasound cranial to the righter mammilla, sized 15 mm in diameter. Utrasound of the axilla showed no suspected lymph nodes. A core biopsy proved an adenocarcinoma. After discussing the different options, the patient preferred a skin-sparing mastectomy with nipple banking and sentinel node biopsy. The sentinel node was retrieved by 85 MBq technetium-99m nanocolloid intra-tumoural injection, without using blue dye. At histopathology the tumour was T1 (15 mm) in size, B&R grade II; the sentinel node was tumournegative after multiple slicing and IHC staining with Cam 5.2; oestrogen receptor was 100% positive and progestin receptor was 100% positive; HER2neu was negative. The margins were free. The Mammaprint showed a low-risk signature, that is no distant metastases within at least 5 years. Since the patient was in her first trimester of pregnancy, and the child was very much desired, finally, the patient opted for endocrine therapy. She will receive tamoxifen and ovarian suppression by LHRH agonist after her child delivery. She decided not to have adjuvant chemotherapy, particularly considering the high hormone responsiveness of the tumour and the Mammaprint low risk. In addition, due to her young age, she was referred to the genetic counselling department.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact breast cancer has on family members/caregivers","authors":"L. Shockney","doi":"10.1017/S1470903109990137","DOIUrl":"https://doi.org/10.1017/S1470903109990137","url":null,"abstract":"","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990137","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Gnant, P. Dubsky, F. Fitzal, P. Blaha, G. Steger, R. Jakesz
{"title":"Adjuvant endocrine therapy in premenopausal women with breast cancer","authors":"M. Gnant, P. Dubsky, F. Fitzal, P. Blaha, G. Steger, R. Jakesz","doi":"10.1017/S1470903109990149","DOIUrl":"https://doi.org/10.1017/S1470903109990149","url":null,"abstract":"Breast cancer is the most common malignancy among women worldwide, and a quarter of all breast cancers are diagnosed in premenopausal women. Adjuvant chemotherapy is well established as the therapy of choice for hormone receptor-negative breast cancers. Historically, ovarian ablation substantially inhibited the progression of hormone-responsive breast cancer. Current adjuvant treatment options for premenopausal patients with hormone receptor-positive breast cancer include endocrine therapy and chemotherapy. Pharmacologic ovarian suppression alone has limited efficacy in the adjuvant setting, but it offers good clinical outcomes when combined with tamoxifen or chemotherapy. In recent years, aromatase inhibitors (AIs) have become the endocrine therapy of choice in postmenopausal women with hormone-responsive breast cancer, but their efficacy in the premenopausal setting is yet to be established. However, in a large, phase III randomized study (Austrian Breast and Colorectal Cancer Study Group Trial 12) that matured earlier this year, the combination of ovarian suppression and AI, anastrozole, did not show superior efficacy compared with ovarian suppression plus tamoxifen, but was associated with fewer serious adverse effects in premenopausal women with early stage hormone-responsive breast cancer. Data from ongoing and future trials will help to further define the role of ovarian suppression and AIs in the adjuvant setting for premenopausal breast cancer.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990149","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Drugs targeting insulin-like growth factor 1 receptor","authors":"T. Mayer, L. Harris, M. DiGiovanna","doi":"10.1017/S1470903109990058","DOIUrl":"https://doi.org/10.1017/S1470903109990058","url":null,"abstract":"14622. 59. Wittman M, Carboni J, Attar R, et al. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 2005; 48(18): 5639–5643. 60. Mulvihill M, Qun-Sheng J, Rosenfeld-Franklin M, et al. The discovery of OSI-906: a novel, potent, orally bioavailable imidazopyrazine-derived insulin-like growth factor-I receptor (IGF-1R) inhibitor with antitumor activity. AACR Annual Meeting 2008: abstract 4893. 61. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63(24): 8912–8921. 62. Cohen B, Baker D, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11(5): 2063–2073. 63. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113(2): 316–328. 64. Maloney E, McLaughlin J, Dagdigian N, et al. An antiinsulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63(16): 5073–5083. 65. Sachdev D, Li S, Hartell J, Fujita-Yamaguchi Y, Miller J, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63(3): 627–635. 66. Wang Y, Hailey J, Williams D, et al. Inhibition of insulinlike growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005; 4(8): 1214–1221. 67. Haluska P, Shaw H, Batzel G, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13(19): 5834–5840. Drugs targeting insulin-like growth factor 1 receptor Page 9 of 10 https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1470903109990058 Downloaded from https://www.cambridge.org/core. IP address: 207.241.231.82, on 24 Jul 2018 at 13:47:50, subject to the Cambridge Core terms of use, available at 68. Lacy M, Alsina M, Fonseca R, et al. Phase I, Pharmacokinetic and Pharmacodynamic Study of the AntiInsulin like Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. J Clin Oncol 2008; 26(19): 3196–3203. 69. Karp D, Paz-Ares L, Novello P, et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 2008; 26: abstract 8015. 70. Hidalgo M, Tirado Gomez M","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Perioperative therapy in HER2+ patients","authors":"R. A’Hern, N. Bundred","doi":"10.1017/S1470903109990034","DOIUrl":"https://doi.org/10.1017/S1470903109990034","url":null,"abstract":"","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nodal micrometastases in early stage breast cancer: two case reports","authors":"J. Reeder, S. Puhalla, V. Vogel","doi":"10.1017/S1470903109990046","DOIUrl":"https://doi.org/10.1017/S1470903109990046","url":null,"abstract":"The most important predictor of outcome for women with early stage breast cancer is the presence or absence of metastases in the axillary lymph nodes. In the era of sentinel lymph node biopsies and improved pathology techniques, micrometastatic disease can be diagnosed. The question of whether or not to treat these women as if they have nodal disease remains in doubt. In order to further explore this topic, we identified two cases of women with nodal micrometastases at our institution. A literature review of PUBMED and SABCS abstracts was then performed. In this article, we discuss our results and the emerging clinical debate about the management of nodal micrometastases.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：